DXNVX Secures Additional Investment of 17 Billion KRW

Following Last Month's 17.8 Billion, Additional Funds Secured Through CB
Accelerating the Establishment of Future Growth Engines

[Asia Economy Reporter Kwangho Lee] DXNVX (formerly Cancerop) announced on the 9th that following the 17.8 billion KRW investment secured last month, it has recently succeeded in raising an additional 17 billion KRW in investment. This round of investment was made through the issuance of convertible bonds (CB).

DXNVX stated, "The fact that a company under trading suspension has successfully attracted approximately 35 billion KRW in external investment twice within a month can be interpreted as institutional investors positively evaluating the growth value reborn through the responsible management commitment shown by major shareholder Jongyoon Lim and the improvement of the management structure."

DXNVX recorded sales exceeding last year's annual performance in the first half of the year and continues its profit trend. It is expected to achieve record-high results with sales of 13 billion KRW and operating profit of 1.1 billion KRW in the first half of this year alone.

The first round of investment funds raised last month will be used to acquire Korea Biopharm, which has GMP production facilities. The company explained that this is to establish an integrated business structure covering research and development, production, and distribution, and to lay the foundation for long-term growth.

DXNVX added, "The second round of investment funds will also be used to acquire tangible and intangible assets to secure future growth engines." Regarding tangible assets, additional GMP production bases will be established, and for intangible assets, pharmaceutical pipelines are expected to be secured.

This content was produced with the assistance of AI translation services.